Department of Internal Medicine I, University of Bonn, Germany.
Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1218-25. doi: 10.1097/MEG.0b013e32834a75dc.
BACKGROUND/AIMS: In cirrhosis portal hypertension can promote bacterial translocation and increase serum endotoxin levels. Vice versa, endotoxin aggravates portal hypertension by induction of systemic and splanchnic vasodilation, and by triggering hepatic inflammatory response via tumor necrosis factor α (TNFα). However, the hepatic elimination of endotoxin in cirrhotic patients with severe portal hypertension, in the absence of acute complications, has not been investigated so far.
Twenty patients with alcoholic liver cirrhosis received transjugular intrahepatic portosystemic shunt at an event-free interval for either refractory ascites or recurrent bleeding. During the transjugular intrahepatic portosystemic shunt procedure portal and hepatic venous blood samples were obtained and endotoxin levels were measured by a chromogenic limulus-assay. In 16 of these patients an enzyme-linked immunosorbent assay was used to measure levels of the soluble TNFα-receptors sTNF-R55 and sTNF-R75.
Portal venous endotoxin levels correlated with portal vein velocity (P=0.03) and arterial systolic blood pressure (P=0.007). Portal endotoxin levels correlated with portal venous sTNF-R75-levels (P=0.039; r=0.521) and hepatic venous sTNF-R55-levels (P=0.009; r=0.669). Hepatic venous levels of both sTNF-R55 and sTNF-R75 correlated directly with the model for end-stage liver disease-score, and inversely with cholinesterase. However, we did not find significant differences in endotoxin levels nor in sTNF-R55-levels and sTNF-R75-levels between portal and hepatic venous blood.
Endotoxin levels correlated with hemodynamic derangement in cirrhotic severe portal hypertension, and with levels of soluble TNFα-receptors. Soluble TNFα-receptor levels correlated with the severity of liver dysfunction. However, in this study an endotoxin concentration gradient across the liver was absent, suggesting negligible primary hepatic endotoxin elimination in the absence of complications.
背景/目的:在肝硬化门静脉高压症中,细菌易位和血清内毒素水平升高。反之,内毒素通过诱导全身和内脏血管舒张,并通过肿瘤坏死因子α(TNFα)触发肝炎症反应,从而加重门静脉高压。然而,在没有急性并发症的情况下,尚未研究严重门静脉高压的肝硬化患者肝脏对内毒素的消除。
20 例酒精性肝硬化患者在无并发症的情况下接受经颈静脉肝内门体分流术,以治疗难治性腹水或复发性出血。在经颈静脉肝内门体分流术过程中,采集门静脉和肝静脉血样,并通过显色鲎试验测量内毒素水平。在其中 16 例患者中,使用酶联免疫吸附试验测量可溶性 TNFα 受体 sTNF-R55 和 sTNF-R75 的水平。
门静脉内毒素水平与门静脉速度(P=0.03)和动脉收缩压(P=0.007)相关。门静脉内毒素水平与门静脉 sTNF-R75 水平相关(P=0.039;r=0.521)和肝静脉 sTNF-R55 水平相关(P=0.009;r=0.669)。两种 sTNF-R55 和 sTNF-R75 的肝静脉水平均与终末期肝病模型评分直接相关,与胆碱酯酶水平呈反比。然而,我们没有发现门静脉和肝静脉血液之间的内毒素水平或 sTNF-R55 水平和 sTNF-R75 水平存在显著差异。
内毒素水平与肝硬化严重门静脉高压症的血液动力学紊乱以及可溶性 TNFα 受体水平相关。可溶性 TNFα 受体水平与肝功能不全的严重程度相关。然而,在这项研究中,肝脏内不存在内毒素浓度梯度,提示在没有并发症的情况下,肝脏对内毒素的初级消除作用可忽略不计。